Project description:The aim of the study is to analyze and compare the transcriptional profiles of tumor-infiltrating Microglia from glioma brearing brain tissues treated with anti-CTLA4 in the presence or absence of CD4 T cells .
Project description:The aim of the study is to analyze and compare the transcriptional profiles of tumor-infiltrating Microglia from glioma brearing brain tissues treated with anti-CTLA4 in the presence or absence of CD4 T cells .
Project description:The aim of the study is to analyze and compare the transcriptional profiles at a single cell resolution of tumor-infiltrating immune cells from healthy mouse brain as well as glioma brearing brain tissues treated with anti-CTLA4 in the presence or absence of CD4 T cells .
Project description:The aim of the study is to analyze and compare the transcriptional profiles at a single cell resolution of tumor-infiltrating immune cells from healthy mouse brain as well as glioma brearing brain tissues treated with anti-CTLA4 in the presence or absence of CD4 T cells .
Project description:The 18 kDa translocator protein (TSPO) emerges as an important PET biomarker to assess the tumor microenvironment (TME) in glioblastoma. However, various cellular sources hamper interpretation and biological understanding of TSPO and other immune biomarkers in the TME. Thus, we established a novel method, combining immunomagnetic cell sorting after radiotracer injection (scRadiotracing) with 3D histology via light sheet microscopy and proteomics to dissect cellular allocation of TSPO enrichment in glioblastoma. Single tumor cells of implanted SB28 glioblastoma mice indicated 1.37-fold higher TSPO tracer uptake and 1.46-fold higher TSPO protein expression levels when compared to tumor associated microglia/macrophages (TAMs). Using proteomics, we compared the proteome of tumor associated microglia/macrophages (TAMs), Tumor tissue (TT) and control microglia from WT mice without glioblastoma. This analysis identified TAM specific targets for PET radioligand development with additional potential to monitor diverse TAM subpopulations in vivo. In summary, our data indicate that tumor cells need to be acknowledged as the main contributor to TSPO as a biomarker in glioblastoma. Combining cellular tracer uptake measures with 3D histology facilitates precise allocation of complex PET signal sources and will serve to validate novel TAM specific radioligands.